During the preclinical development of TAVO412, the antitumor effects were evaluated in various tumor cell line-derived xenograft (CDX) models as well as in patient-derived tumor (PDX) models with different EGFR and c-Met expression levels and mutations. The gene discussed is EGFR; the disease is neoplasm.